A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

A new pill that ‘slows down Alzheimer's ' is being considered for use in the NHS. Developed by a small British firm in ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) ...

The study also integrates drug databases ... Women With Ovarian Removal Have Unique Risk and Resilience Factors for Alzheimer Disease Dec. 5, 2024 — New research has found that women who have ...

Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due ...

It raises the prospect of it being the third successive drug in a new era of Alzheimer’s treatments to not be approved for NHS patients amid concerns that Nice’s cost assessments of the ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...